Antimikrobielle Prophylaxe und Therapie bei neutropenischen Patienten

  • H.-P. Lipp
  • H. Hebart
  • C. Faul
  • H. Einsele


Einen großen Stellenwert im Rahmen der supportiven Therapie bei Patienten mit malignen Erkrankungen und hochdosierter chemotherapeutischer Behandlung hat die optimale Infektionsprophylaxe während der Neutropenie und die gezielte Intervention bei manifestem Fieber.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur zu 2

  1. Alavi JB, Root RK, Djerassi I et al. (1977) A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med 296: 706–711PubMedCrossRefGoogle Scholar
  2. Anaissie EJ, Darouiche RO, Abi Said D et al. (1996) Management of invasive candidal infections: Results of a prospective randomized multicenter study of fluconazole vs. amphotericin B and review of the literature. Clin Infect Dis 23: 964–972PubMedCrossRefGoogle Scholar
  3. Arning M, Wolf HH, Aul C et al. (1990) Infection prophylaxis in neutropenic patients with acute leukemia — a randomized, comparative study with ofloxacin, ciprofloxacin and co-trimoxazole/colistin. J Antimicrob Chemother 26 (Suppl D): 137–142PubMedGoogle Scholar
  4. Barnes AJ, Wardley AM, Oppenheim et al. (1996) Fatal Candida tropicalis fungemia in a leukaemic patient receiving fluconazole prophylaxis. J Infection 33: 43–45CrossRefGoogle Scholar
  5. Bochud P-Y, Calandra T, Francioli P (1994) Bacteremia due to viridans streptococci in neutropenic patients: A Review. Am J Med 97: 256–264PubMedCrossRefGoogle Scholar
  6. Bodey G, Bueltmann B, Duguid W et al. (1992) Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 11: 99–109PubMedCrossRefGoogle Scholar
  7. Bodey GP,Anaissie EJ, Elting LS et al. (1994) Antifungal prophylaxis during remission induction therapy for acute leukemia. Fluconazole vs. intravenous amphotericin B Cancer 73: 2099–2106Google Scholar
  8. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64: 328–339PubMedGoogle Scholar
  9. Böhme A, Just-Nübling G, Bergmann L et al. (1996) Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother 38: 953–961PubMedCrossRefGoogle Scholar
  10. Boogaerts MA (1995) Anti-infective strategies in neutropenia. J Antimicrob Chemother 36(Suppl A): 167–178PubMedGoogle Scholar
  11. Bow EJ, Loewen R, Vaughan D (1995) Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemotherapy with oral quinolones. Clin Infect Dis 20: 907–912PubMedCrossRefGoogle Scholar
  12. Buckner CD, Gift RA, Thomas ED et al. (1983) Early infectious complications in allogeneic marrow transplant recipients with acute leukemia: effects of prophylactic measures. Infection 11: 243–250PubMedCrossRefGoogle Scholar
  13. Cornelissen JJ, Rozenberg-Arska M, Dekker AW (1995) Discontinuation of intravenous antibiotic therapy during persistent neutropenia in patients receiving prophylaxis with oral ciprofloxacin. Clin Infect Dis 21: 1300–1302PubMedCrossRefGoogle Scholar
  14. De Marie S, Van den Broek PJ, Willemze R, Van Furth R (1993) Strategy for antibiotic therapy in febrile neutropenic patients on selective antibiotic decontamination. Eur J Clin Microbiol Infect Dis 12: 897–906PubMedCrossRefGoogle Scholar
  15. De Pauw BE, Dompeling EC (1996) Antibiotic strategy after the empiric phase in patients treated for haematological malignancy. Ann Hematol 72: 273–279PubMedCrossRefGoogle Scholar
  16. Del Favero A, Menichetti F (1993) The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients. Eur J Cancer 29 A (Suppl 1): S2–S6Google Scholar
  17. Donnelly JP (1995) Bacterial complications of transplantation: diagnosis and treatment. J Antimicrob Chemother 36 (Suppl B), 59–72PubMedGoogle Scholar
  18. Einsele H, Ehninger G, Hebart H et al. (1995) PCR-monitoring after BMT to reduce the incidence of CMV disease and the duration and side effects of antiviral therapy. Blood 86: 2815–2820PubMedGoogle Scholar
  19. Ellis ME, Spence D, Ernst P, Greer W (1997) Variability of plasma fluconazole levels in patients with hematologic malignancy. Clin Infect Dis 24: 86–87PubMedCrossRefGoogle Scholar
  20. Foot AB, Garin YJ, Ribaud P et al. (1994) Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients. Bone Marrow Transplant 14: 241–245PubMedGoogle Scholar
  21. Fortuny IE, Bloomfield CD, Hadlock DC et al. (1975) Granylocyte transfusion: a controlled study in patients with acuute nonlymphocytic leukemia. Transfusion 15: 548–558PubMedCrossRefGoogle Scholar
  22. Goodman JL, Winston DJ, Greenfield RA et al. (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326: 845–851PubMedCrossRefGoogle Scholar
  23. Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A (1993) Treatment of Candida albicans fungemia with fluconazole. J Infect Dis 26: 133–146Google Scholar
  24. Graw RG, Jr., Herzig G, Perry S, Henderson ES (1972) Normal granulocyte transfusion therapy: treatment of septicemia due to gram-negative bacteria. N Engl J Med 287: 367–371PubMedCrossRefGoogle Scholar
  25. Guglielmo BJ, Jacobs RA (1996) Impact of dosage-monitoring system on frequency of seizures associated with imipenem-cilastatin. Am J Health Syst Pharm 53: 2097–2098PubMedGoogle Scholar
  26. Guiot HFL, Fibbe WE, van’t Wout JW (1994) Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 18: 525–532PubMedCrossRefGoogle Scholar
  27. Hatala R, Dinh TT, Cook DJ (1997) Single daily dosing of aminoglycosides in immunocompromised adults: A systematic review. Clin Inf Dis 24: 810–815CrossRefGoogle Scholar
  28. Hebart H, Schröder A, Löffler J et al. (1997) CMV-monitoring by PCR of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation. J Infect Dis 175: 1490–1493PubMedCrossRefGoogle Scholar
  29. Heinemann V, Kähny B, Jehn U et al. (1997) Serum pharmacology of amphotericin B applied in lipid emulsions. Antimcrob Agents Chemother 41: 728–732Google Scholar
  30. Hertenstein B, Kern WV, Schmeiser T et al. (1994) Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol 68: 21–26PubMedCrossRefGoogle Scholar
  31. Herzig RH, Herzig GP, Graw RG Jr., Bull MI, Ray KK (1977) Successful granulocyte transfusion therapy for gram-negative septicemia. A prospectively randomized controlled study. N Engl J Med 296: 701–705PubMedCrossRefGoogle Scholar
  32. Hester JP, Dignani MC, Anaissie EJ et al. (1995) Collection and transfusion of granulocyte concentrates from donor primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. J Clin Apheresis 10: 188–193PubMedCrossRefGoogle Scholar
  33. Hiddemann W, Maschmeyer G, Runde V, Einsele H (1996) Prophylaxe, Diagnostik und Therapie von Infektionen bei Patienten mit malignen Erkrankungen. Internist 37: 1212–1224PubMedGoogle Scholar
  34. Higby DJ, Yates JW, Henderson ES, Holland JF (1975) Filtration leukapheresis for granulocyte transfusion therapy. Clinical and laboratory studies. N Engl J Med 292: 761–766PubMedCrossRefGoogle Scholar
  35. Höffken K (1995) Antibiotische Therapie beim neutropenischen Fieber. Onkologe 1: 503–510Google Scholar
  36. Hughes WT, Armstrong D, Bodey GP et al. (1990) Guidelines for the use of antimocrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161: 381–396PubMedCrossRefGoogle Scholar
  37. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS (1996) A Meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 156: 177–188PubMedCrossRefGoogle Scholar
  38. Kelsey SM, Weinhardt B, Pocock CE, Shaw E, Newland AC (1992) Piperacillin/Tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients. J Chemother 4/5: 281–285PubMedGoogle Scholar
  39. Klastersky J (1995) Prevention and therapy of fungal infections in cancer patients. A review of recently published information. Support Care Cancer 3: 393–401PubMedCrossRefGoogle Scholar
  40. Kumana CR, Yuen KY (1994) Parenteral aminoglycoside therapy — selection, administration and monitoring. Drugs 47/6: 902–913PubMedCrossRefGoogle Scholar
  41. Link H, Maschmeyer G, Meyer P et al. for the Study Group of the Paul Ehrlich Society for Chemotherapy (1994) Interventional antimocrobial therapy in febrile neutropenic patients. Ann Hematol 69: 231–243PubMedCrossRefGoogle Scholar
  42. Lipp H-P (1997) Amphotericin B und seine Lipid-Carrier — eine kritische Übersicht. Krankenhauspharmazie 18: 104–113Google Scholar
  43. Lipp H.-P (1996) Klinische Pharmakokinetik von Itraconazol. Krankenhauspharmazie 17: 388–395Google Scholar
  44. Mahendra P, Jacobson SK, Ager S et al. (1996) Short-course intravenous antibiotics with oral quinolone prophylaxis in the treatment of neutropenic fever in autologous bone marrow or peripheral blood progenitor cell transplant recipients. Acta Haematol 96: 64–67PubMedCrossRefGoogle Scholar
  45. Maschmeyer G (1993) Use of the quinolones for the prophylaxis and therapy of infections in immunocompromised hosts. Drugs 45 (Suppl 3): 73–80PubMedCrossRefGoogle Scholar
  46. Menichetti F, Del Favero A, Martino P et al. (1994) Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B.Ann Intern Med 120: 913–918PubMedGoogle Scholar
  47. Momin F, Chandrasekar PH (1995) Antimicrobial prophylaxis in bone marrow transplantation. Ann Intern Med 123: 205–215PubMedGoogle Scholar
  48. N.N. (1996) Empirische antimikrobielle Therapie bei febrilen Episoden. Arzneimittelbrief 30: 9–12Google Scholar
  49. Nicolau DP,Wu AHB, Finocchiaro S et al. (1996) Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Ther Drug Monit 18: 263–266PubMedCrossRefGoogle Scholar
  50. Persat F, Marzullo C, Guyotat D, Rochet MJ, Piens MA (1992) Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 28 A, 838–841CrossRefGoogle Scholar
  51. Preston SL, Briceland LL (1995) Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia. Am J Health Syst Pharm 52: 164–173PubMedGoogle Scholar
  52. Preston SL, Briceland LL, Lamaestro BM et al. (1995) Dosing adjustment of 10 antimicrobials for patients with renal impairment. Ann Pharmacother 29: 1292–1207Google Scholar
  53. Rahmann Z, Esparaza-Guerra L, Yap H-Y et al. (1997) Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapy. Cancer 79: 1150–1157CrossRefGoogle Scholar
  54. Riley DK, Pavia AT, Beatty PG et al (1994) The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 97: 509–514PubMedCrossRefGoogle Scholar
  55. Ruhnke M, Beyer J (1997) Antimykotische Prophylaxe bei neutropenischen und immunsupprimierten Patienten. Med Klin 92: 28–36CrossRefGoogle Scholar
  56. Sable CA, Donowitz GR (1994) Infections in bone marrow transplant recipients. Clin Infect Dis 18: 273–284PubMedCrossRefGoogle Scholar
  57. Safrin S, Lee BL, Sande MA (1994) Adjunctive folinic acid with triemthoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J Infect Dis 170: 912–917PubMedCrossRefGoogle Scholar
  58. Sanders WE, Sanders CC (1996) Piperacillin/tazobactam: A critical review of the evolving clinical literature. Clin Infect Dis 22: 107–123PubMedCrossRefGoogle Scholar
  59. Slavin MA, Osborne B, Adams R et al. (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation — A prospective randomized double-blind Study. J Infect Dis 171: 1545–1552PubMedCrossRefGoogle Scholar
  60. Ter Braak EW, De Vries PJ, Bouter KP et al. (1990) Once-daily dosing regimen for aminoglycosides plus β-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 89: 58–66PubMedCrossRefGoogle Scholar
  61. Thomson AH, Duncan N, Silverstein B, Alcock S, Jodrell D (1996) Development of guidelines for gentamicin dosing. J Antimicrob Chemother 38: 885–893PubMedCrossRefGoogle Scholar
  62. Verhoef J (1993) Prevention of infections in the neutropenic patient. Clin Infect Dis 17 (Suppl 2): S359–367PubMedCrossRefGoogle Scholar
  63. Vogler WR, Winton EF (1977) A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia. Am J Med 63: 548–555PubMedCrossRefGoogle Scholar
  64. Winston DJ, Ho WG, Gale RP (1982) Therapeutic granulocyte transfusions for documented infections. A controlled trial in ninety-five infectious granulocytopenic episodes. Ann Intern Med 97: 509–515PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • H.-P. Lipp
  • H. Hebart
  • C. Faul
  • H. Einsele

There are no affiliations available

Personalised recommendations